Grants per year
Personal profile
Training Experience
| 2009 | Residency, Rush University Medical Center |
| 2012 | Fellowship, Rush University Medical Center |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MS, Clinical Research, Rush University
… → 2012
MD, Medicine, Western University
… → 2006
Fingerprint
Dive into the research topics where Reem Karmali is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #M22-003: A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Karmali, R. (PD/PI)
11/22/24 → 11/22/27
Project: Research project
-
Prot #NU 23H05: Phase II, Single arm, Open label, study of the combination of Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following Autologous Stem Cell Transplantation (ASCT) or Chimeric Antigen Receptor (CAR) T-cell therapy in Patients
Karmali, R. (PD/PI)
9/23/24 → 9/23/27
Project: Research project
-
Prot #GO44145: A Phase III, Multicenter, Randomized, Open-Label Study Comparing The Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophospamide, Doxorubicin, and Prednisone (POLA-R-CHP) Versus POLA
Karmali, R. (PD/PI)
7/18/24 → 5/31/29
Project: Research project
-
Prot #CRG‐022‐101: An Open‐label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG‐022, a CD22‐Directed Autologous Chimeric Antigen Receptor (CAR) T‐cell Therapy in Patients With Relapsed/Refractory Large B‐Cell Lymphoma After CD19‐Dire
Karmali, R. (PD/PI)
Novella Clinical, LLC, CARGO Therapeutics, Inc.
5/24/24 → 4/30/26
Project: Research project
-
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy
Karmali, R., Shouse, G., Torka, P., Moyo, T. K., Romancik, J., Barta, S. K., Bhansali, R., Cohen, J. B., Shah, N. N., Zurko, J., Kenkre, V. P., Hess, B., Stephens, D. M., Fitzgerald, L., Ollila, T., Tabiti, B., Roy, I., Ma, S., Winter, J. N. & Pro, B. & 5 others, , Dec 2025, In: Blood cancer journal. 15, 1, 43.Research output: Contribution to journal › Article › peer-review
Open Access -
Mosunetuzumab next up to bat … is it a home run?
Karmali, R. & Winter, J. N., Feb 13 2025, In: Blood. 145, 7, p. 655-657 3 p.Research output: Contribution to journal › Editorial › peer-review
-
Variance in development of early and late cardiotoxicities in patients with lymphoma and myeloma receiving CAR T-cell therapies
Grunblatt, E., Meng, Z., Baldridge, A. S., Patel, N. P., Stanisic, A., Feinstein, M. J., Rao, A., Gordon, L. I., Winter, J. N., Ma, S., Mehta, J., Singhal, S., Karmali, R. & Akhter, N., 2025, (Accepted/In press) In: Leukemia and Lymphoma.Research output: Contribution to journal › Article › peer-review
-
Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study
Tun, A. M., Patel, R. D., St-Pierre, F., Ouchveridze, E., Niu, A., Thordardottir, T., Obasi, J., Rosenthal, A., Pophali, P. A., Fenske, T. S., Karmali, R., Ahmed, S. & Johnston, P. B., Sep 2024, In: American Journal of Hematology. 99, 9, p. 1712-1720 9 p.Research output: Contribution to journal › Article › peer-review
2 Scopus citations -
A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen
Karmali, R., Galvez, C., Hamadani, M., Gordon, L., Winter, J., Ma, S., Nelson, V., Fenske, T. S., Shah, N. N., Jagadeesh, D., Klein, A., Helenowski, I., Chen, R., Mi, X., Petrich, A., Evens, A. M. & Pro, B., Apr 9 2024, In: Blood Advances. 8, 7, p. 1612-1620 9 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations
Datasets
-
Impact of early relapse within 24 months after first-line systemic therapy (POD24) on outcomes in patients with marginal zone lymphoma: A US multisite study
Epperla, N. (Creator), Welkie, R. L. (Creator), Torka, P. (Creator), Shouse, G. (Creator), Karmali, R. (Creator), Shea, L. (Creator), Anampa-Guzmán, A. (Creator), Oh, T. S. (Creator), Reaves, H. (Creator), Tavakkoli, M. (Creator), Lindsey, K. (Creator), Greenwell, I. B. (Creator), Hansinger, E. (Creator), Thomas, C. (Creator), Chowdhury, S. M. (Creator), Annunzio, K. (Creator), Christian, B. (Creator), Barta, S. K. (Creator), Geethakumari, P. R. (Creator), Bartlett, N. L. (Creator), Herrera, A. F. (Creator), Grover, N. S. (Creator) & Olszewski, A. J. (Creator), figshare, 2023
DOI: 10.6084/m9.figshare.c.6638327, https://springernature.figshare.com/collections/Impact_of_early_relapse_within_24_months_after_first-line_systemic_therapy_POD24_on_outcomes_in_patients_with_marginal_zone_lymphoma_A_US_multisite_study/6638327
Dataset